Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
Acumen Pharmaceuticals reported a Q2 net loss of $32.7 million, or ($0.45) per share, narrowing from a $41.0 million loss in the prior-year quarter as R&D expenses decreased to $27.8 million. The company holds $110.2 million in cash and equivalents, which management expects will support clinical and operational activities into early 2027.
Key figures
- Runway
- into early 2027
- Net loss
- $32.7 million
- Rd expenses
- $27.8 million
- Phase 2 readout timing
- late 2026
- Cash equivalents and securities
- $110.2 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.